A subset of thyroid cancers is initiated by gene rearrangements involving receptor tyrosine kinase (RTK) genes, such as RET, ALK and NTRK (5–10%), that also activate the MAPK pathway (Table 2) (2, 17, 18, 19, 20, 21). The gene discussed is RET; the disease is thyroid gland carcinoma.